Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation
  • Ask Questions

Author: Tamas Sohajda

Cyclolab R&D Director
January 14, 2021 Drug delivery / Pharma applications

Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder (CDD)

Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders,

Continue reading

January 11, 2021 CD as API / CD derivatives / Drug delivery / Pharma applications

Cyclolab and EpiPharma Form Joint Venture company Targetrin Therapeutics to Develop and Commercialize novel conjugated Cyclodextrin – Peptide drugs

Cyclolab, the oldest, world renowned cyclodextrin research, development and manufacturing company, and EpiPharma, a bio-pharmaceutical services and peptide drug development

Continue reading

January 8, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C

Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo

Continue reading

December 11, 2020 Drug delivery / Pharma applications

Marinus Pharmaceuticals Provides SBECD-enabled Ganaxolone Clinical Data

Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced it

Continue reading

December 11, 2020 Drug delivery / Pharma applications

Top-line final data from CD-enabled Cantrixil Phase I study confirms prior positive efficacy and safety signals

Kazia Therapeutics Limited, an Australian oncology-focused biotechnology company shared top-line final data from its phase I study of Cantrixil (TRX-E-002-1)

Continue reading

December 10, 2020 CD as API / Events / Pharma applications

Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering

Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin

Continue reading

November 11, 2020 Drug delivery / Non-pharma applications / Other industrial use / Pharma applications / Uncategorized

FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH

The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by

Continue reading

November 9, 2020 Drug delivery / Pharma applications

Sedor Pharmaceuticals Receives FDA Approval for SESQUIENT™ (SBECD-enabled fosphenytoin)

Ligand Pharmaceuticals Incorporated announced that its partner Sedor Pharmaceuticals, LLC has received approval from the U.S. Food and Drug Administration

Continue reading

October 24, 2020 Drug delivery / Pharma applications

U.S. FDA Approves Gilead’s Antiviral Veklury® (remdesivir) for Treatment of COVID-19

— Veklury Is First and Only FDA-Approved Treatment for COVID-19 in the United States — — Veklury Shortened Time to

Continue reading

October 21, 2020 CD as API / CD derivatives / Pharma applications / Uncategorized

New cyclodextrin with orphan drug designation: SBECD

ReVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular

Continue reading

Posts navigation

1 2 3 … 11 Next Posts»

Recent Posts

  • β-cyclodextrin and ion-doped polypyrrole composite nanomaterials as electrodes for seawater desalination
  • Roquette on the role of cyclodextrins in vaccines
  • CD-based Nanoparticles from CNR-ISMN Institute of Nanostructured Materials
  • Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder (CDD)
  • Changes in the management of CycloLab

Tags

antiviral Betadex Sulfobutyl Ether Sodium Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems Drugs FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease Polymer RAMEB remdesivir SBECD Special issue Synthesis

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (7)
  • Analysis (12)
  • CD as API (93)
  • CD derivatives (117)
  • Cosmetics and toilettry (10)
  • Drug delivery (181)
  • E-ducation (40)
  • Environmental (38)
  • Events (91)
  • Food (53)
  • Gene delivery (6)
  • In Hungarian (4)
  • Non-pharma applications (91)
  • Other industrial use (33)
  • Pharma applications (333)
  • Supramolecular systems (7)
  • Uncategorized (21)

Top Posts

  • Roquette on the role of cyclodextrins in vaccines
  • β-cyclodextrin and ion-doped polypyrrole composite nanomaterials as electrodes for seawater desalination
  • Changes in the management of CycloLab
  • Special Issue "Pharmaceutical and Biomedical Applications of Cyclodextrins and Derivatives"
  • Remdesivir dry powder inhalation formulation, pharmacokinetic study in hamsters
  • Nasal delivery with beta-cyclodextrin is approved; a short story of Baqsimi
  • Gilead to Test a Version of Remdesivir That Can Be Inhaled
  • How air fresheners work?
  • Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C
  • Nitric oxide in the treatment of coronavirus disease (COVID-19)

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 278 other subscribers